Larimar resumes nomlabofusp programme after FDA lifts partial hold
Larimar will continue the open label extension study in Friedreich’s ataxia with results expected in Q4 this year.
Larimar will continue the open label extension study in Friedreich’s ataxia with results expected in Q4 this year.
The Annual Outsourcing in Clinical Trials conference will gather pharma experts to discuss the UK clinical trial landscape.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Rakovina expands collaborations to leverage AI platform
Biotechs must prioritise ethics to deter GenAI “bad actors”
AstraZeneca to withdraw Covid-19 vaccine globally
GSK, Lundbeck, ROVI: Three Journeys of Unified Pharma Events Management